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Abstract. Mammary gland development is controlled 
by systemic hormones and by growth factors that 
might complement or mediate hormonal action. Pep- 
tides that locally signal growth cessation and stimulate 
differentiation f the developing epithelium have not 
been described. Here, we report hat recombinant and 
wild-type forms of mammary-derived growth inhibitor 
(MDGI) and heart-fatty acid binding protein (FABP), 
which belong to the FABP family, specifically inhibit 
growth of normal mouse mammary epithelial cells 
(MEC), while growth of stromal cells is not sup- 
pressed. In mammary gland organ culture, inhibition 
of ductal growth is associated with the appearance of
bulbous alveolar end buds and formation of fully de- 
veloped lobuloalveolar structures. In parallel, MDGI 
stimulates its own expression and promotes milk pro- 
tein synthesis. Selective inhibition of endogenous 
MDGI expression i  MEC by antisense phos- 
phorothioate oligonucleotides suppresses appearance of
alveolar end buds and lowers the ~-casein level in or- 
gan cultures. Furthermore, MDGI suppresses the 
mitogenic effects of epidermal growth factor, and 
epidermal growth factor antagonizes the activities of 
MDGI. Finally, the regulatory properties of MDGI 
can be fully mimicked by an l 1-amino acid sequence, 
represented in the COOH terminus of MDGI and a 
subfamily of structurally related FABPs. This peptide 
does not bind fatty acids. To our knowledge, this is 
the first report about a growth inhibitor promoting 
mammary gland differentiation. 
ROWTH development, and differentiation fepithelial 
tissues are multistage processes that are driven by 
a combination of paracrine and autocrine signaling 
factors and interactions of a cell with its extracellular matrix 
(reviewed in 51, 60, 62). In the mammary gland, these com- 
plex interactions are regulated by various teroid and peptide 
hormones (29, 32, 46, 60). Development ofthe mouse mam- 
mary gland at puberty ischaracterized by sparsely branching 
ducts which invade the stroma, followed by the development 
of lobuloalveolar structures and functional differentiation, 
i.e., synthesis of milk constituents atpregnancy (1, 17, 32). 
By use of endocrine ablation (44), organ culture systems 
(1, 35, 54, 65) and mammary cells (MEC) ~ growing on a 
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basement membrane (39, 63), it has been documented that 
several steroid hormones in conjunction with prolactin and 
insulin regulate this process (reviewed in reference 66). Al- 
though the systemic importance ofhormones such as estro- 
gen, progesterone, prolactin, cortisol, and growth ormone 
in the development of the mammary gland has been well 
documented, these hormones virtually lack growth stimula- 
tory or inhibitory activities in vitro (32, 46). This has 
prompted a search for polypeptide growth factors that might 
locally mediate or complement action of systemic hormones. 
A number of growth factors that either stimulate or inhibit 
epithelial DNA synthesis n the murine mammary gland have 
been described (32). For example, mitogenic effects on MEC 
have been described for epidermal growth factor (EGF) (16, 
27, 65, 70) and TGF ot (55, 59), demonstrating the impor- 
tance of these growth factors for ductal growth and lobuloal- 
veolar development. TGF-/~I has been shown to inhibit duc- 
tal outgrowth in the mammary gland of virgin mice (47, 53). 
In addition, the same molecule can inhibit functional differ- 
entiation in vitro (41, 50), and it impairs differentiation and 
milk protein synthesis in mice (34). 
In contrast to these reports, there are no available data that 
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describe growth inhibitory and differentiation stimulatory 
growth factor activities during functional differentiation of 
the mammary gland. 
When we screened for epithelial growth inhibitors, we 
have detected and purified from lactating bovine mammary 
gland (7) and from milk fat globule membranes (12) the 
mammary-derived growth inhibitor (MDGI) and a COOH- 
terminally truncated form of MDGI (13). The 14.5-kD 
protein was sequenced (7), and its eDNA was cloned (38). 
Originally, MDGI has been discovered according to its 
growth inhibitory activities on breast cancer cells in vitro 
(8). Our studies on MDGI mRNA and protein expression in 
the developing bovine and mouse mammary gland revealed 
a strong correlation between expression of MDGI in MEC 
and differentiation (6, 38, 43). MDGI expression was found 
to be hormonally regulated (6), suggesting a local role of the 
growth inhibitor in mediating or complementing hormonal 
action during differentiation (23, 24). 
MDGI belongs to a multigene family of conservative pro- 
teins, referred to as fatty acid binding proteins (FABP), 
known to bind long-chain fatty acids, retinoids, and eicosa- 
noids (reviewed in references 21, 40, 68, 69). A striking ho- 
mology was evident between MDGI and the heart fatty acid 
binding protein (FABP) (H-FABP), which differ only in 10 
positions of the amino acid sequence (7), and most likely 
represent isoforms that are encoded by the same gene (67). 
Other closely related members include the FABPs found in 
the brain and the cellular retinoic acid binding protein 
(CRABP) (52, 14, 56, 68). The function of these proteins is 
not yet defined, although a role in fatty acid transport, se- 
questration, or metabolism has been widely discussed (21, 
69). Evidence for the existence of physiologically interesting 
FABP ligands such as selenium (4), E-type prostaglandins 
(18), or hydroxyeicosatetraenoic acid (48), as well as mitosis- 
associated expression of liver FABP (36), gave rise to specu- 
lations of some role of FABP in growth control. 
To address directly the question of a role for MDGI and 
H-FABP as growth inhibitors and differentiation factors of 
MEC, we have cultured primary mouse mammary epithelial 
cells and whole mouse mammary glands in presence of wild- 
type, recombinant as well as mutated MDGI and H-FABP 
forms. We show that MDGI and H-FABP inhibit epithelial 
DNA synthesis, promote morphological differentiation, and 
stimulate milk protein synthesis. Selective inhibition of 
MDGI expression in organ cultures suppresses alveolar 
budding and impairs r-casein synthesis. The MDGI and 
H-FABP properties do not require fatty acid binding, and can 
be fully mimicked by a peptide that comprises COOH- 
terminal amino acids conservatively maintained in a sub- 
group of MDGI-related FABPs. This first report about a 
manunary epithelial differentiation factor suggests that other 
members of the FABP family might similarly to MDGI regu- 
late growth and differentiation. 
Materials and Methods 
Cell and Organ Culture 
Primary Cultures from Mammary Glands of Adult Virgin Mice. Mam- 
mary cells were collected after collagenase digestion of mammary glands 
excised from 8- to 13-wk-old mice. Approximately 105 cells were plated 
onto plastic culture dishes (60 mm in diameter) and maintained in DME 
supplemented with 10 % fetal calf serum, penicillin, streptomycin, 4 #g/ml 
of insulin, and 10 ng/rrd EGE 
Mammary Gland Organ Culture. Whole second thoracic mammary 
glands of hormonally primed virgin mice were cultured in serum-free 
medium according to Banarjee t al. (2). 4-wk-old BALB/c mice were in- 
jected subcutaneously fornine consecutive days with I nag progesterone and 
1 #g estradiol (Jenapharm, Jena, Germany). The second pair of thoracic 
glands was excised and cultivated for 5 d as whole organ on perforated cy- 
ciopore membranes (No. 3090; Falcon Plastics, Cockeysville, MD) in- 
serted into wells of culture plates (No. 3046; Falcon Plastics) in 2 ml 
medium 199 with Hanks' salts (Gibco BRL, Gaithersburg, MD) and 50 
#g/ml gentamycin i  an atmosphere of 50% 02/5% COz, with medium 
changes every 2 d. The medium was supplemented with aldosterone (No. 
12050; Serva, Sigma, Germany), ovine-prolactin (31 IU/mg, No. L-6520; 
Germany), insulin (Berlin-Chemie, Berlin, Germany) (each at 5 #g/mi), 
and 1 #g/ml hydrocortisone (No. 24608; Merck, Darmstadt, Germany), 
and will be referred to in this paper as the APIH medium. This medium 
has been used in all experiments described below. EGF was prepared as de- 
scribed before (58). Generally, three pairs of contralateral glands represent- 
ing control and test groups were examined. 
Histology and Morphometry 
Whole-mount hematoxylin stains of mammary glands were obtained as de- 
scribed (49). For histology, formalin-fixed glands were embedded in 
paraffin. 5-#m sections were cut, deparaffinized, stained with hematoxylin 
and eosin, and analyzed as described before (6). Histologic riteria used 
were as follows (6): for ductules, a linear coat of cubic epithelial cells with- 
out adjacent mesenchyme and signs of secretion; for alveoli, presence of 
secretory cells with vacuoles and luminal secretion. Only structures xhibit- 
ing lumina were counted. At least hree pairs of contraiateral glands were 
examined. Fat droplet index was defined as the quotient of the number of 
alveoli consisting of >50% of epithelial cells with intraepithelini fat droplets 
to the total number of alveoli. Alveolar secretion was defined as the quotient 
of the number of aiveoli with lumina containing secretory products to the 
total number of alveoli. An experimental group comprised of ,~500 differ- 
ent structures for the morphometric analysis. 
DNA Synthesis and Immunocytochemistry 
Primary Cultures. To estimate DNA synthesis, cells were seeded at a 
density of 2 x 106 cells in 60-mm dishes in DME containing 10% FBS. 
12 h later, the peptide to be tested was added. Cultures were maintained 
for 48 h before 5-bromo-2'-deoxyuridine (BrdU) at 10 #M was added ac- 
cording to the manufacturer's in tructions (Boehringer Mannheim GmbH, 
Mannheim, Germany). For BrdU staining, cultures were washed three 
times with PBS and fixed in 70% ethanoi/glycine (50 mM, pH 2.0) for 30 
rain at -20°C. Cells were first incubated with 1:10 diluted anti BrdU antise- 
rum, followed by an incubation with a secondary anti-mouse IgG con- 
jugated to alkaline phosphatase. Bromo chloro indolyl phosphate/nitro blue 
tetrazolium (BCIP/NBT) was used as substrate. Colonies >1,000 cells were 
counted. On the average, 10-20 colonies were analyzed for BrdU immuno- 
staining. Results (expressed as percent of the control, which received the 
appropriate buffer) were obtained from triplicate experiments (SD = 
+20%). 
Mammary Gland Organ Culture. Growth inhibition was determined by 
labeling cells with BrdU (100 #M) for 4 h before cultures were terminated. 
Then organ cultures were fixed in 4% formalin/0.5% trichloroacetic a id 
before embedding. Deparaffinized sections were washed in PBS and ana- 
lyzed as described above with the anti-BrdU antiserum kit (Boehringer 
Mannheim GmbH). Sections were counterstained with fast nuclear ed and 
the labeling index (LI) estimated as described before (6). At least 1,000 
nuclei were counted for each experimental group and histologic structure. 
Percent inhibition = 100-LI treated/LI controls x 100. Immunohistochem- 
ical analysis for expression of MDGI and t-casein in tissue sections of a 
mammary gland was performed as described before (38, 43). Depar- 
affinized sections were analyzed with a rabbit anti-mouse t-casein antise- 
rum or an afffinity-purified IgG fraction of a rabbit antiserum against bovine 
MDGI (43). For staining, sections were washed with PBS and treated with 
the streptavidin-biotinylated peroxidase complex (1:200) (Amersham Inter- 
national, Amersham, IL) using diaminobenzidine as substrate. Sections 
were counterstained with hematoxylin. 
RNA Preparation and Northern Blot Analysis 
All methods for analyzing mRNA expression i  cultures from mammary 
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glands were used exactly as described before (6). Total RNA was extracted, 
denatured, and applied to 1% agarose gels for transfer to Hybond C-extra 
membranes (Amersham International) by capillary blotting. Levels for 
mRNAs were estimated from Northern blots hybridized with 32p-labeled 
eDNA probes for MDGI,/~-casein, and whey acidic protein (WAP), and 
were normalized to 28S ribosomal RNA, as described arlier (6). The 0.4- 
kD eDNA probe in pBR327 for WAP was provided by Dr. N. Hynes 
(Friedrich Miescher Institute, Basel, Switzerland). 
Synthesis and Application of Oligonucleotides 
The 17-mer phosphothioate oligonueleotides were synthesized and purified 
Figure 1. Growth inhibition of primary mouse MEC by MDGI. (A) Inhibition 
of epithelial DNA synthesis. Immunostains show epithelial (a and c) and stromal 
(b and d) cells in absence (a and b) and presence of MDGI (c and d). Cells de- 
rived from mammary glands of adult mice were seeded at a density of 2 x 106 
cells. 12 h later, wild-type MDGI was added at 10 -9 M. Cultures were main- 
tained 48 h before BrdU was added for immunostaining (B). Effects of recom- 
binant and wild-type FABPs on epithelial DNA synthesis. DNA synthesis ex- 
pressed as the percent of inhibition was estimated from primary cultures treated 
with the corresponding MDGI and FABP forms and subsequently stained for 
BrdU incorporation as described before. None of the peptides inhibited stromal 
DNA synthesis. Native MDGI, recombinant MDGI, and liver FABP slightly 
stimulated DNA synthesis in stromal cells by 12, 18, and 19%, respectively. Na- 
tive and recombinant FABP were inactive. Colonies >1,000 cells were counted. 
Proteins were added at 10-9 M. Results were obtained from triplicate experi- 
ments (SD = +20%). Bar, 50 #m. 
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Figure 2. Effects of MDGI on mammary gland morphology and differentiation. Whole mouse mammary glands were cultured for 5 d 
in the APIH medium in the presence or absence of MDGI. Morphology: (A and C) Control contralateral g and. (B and D) Mammary 
glands treated with 10 -9 M of wild-type MDGI (15 ng/ml). Same typical result was obtained with recombinant MDGI, and with recom- 
binant or wild-type H-FABP. Arrows indicate alveolar buds formed in presence of MDGI. Histology: (E) Control. (F) MDGI treated. 
Sections of whole mammary glands tained with hematoxylin/eosin how upon MDGI treatment a secretory active and monolayered epithe- 
lium surrounding enlarged lumina. Note fat droplets accumulation i alveolar epithelial cells. Bar, 50/zm./3-casein immunostaining: (G) 
Control. (H) MDGI treated. MDGI immunostaining: (I) Control. (J) MDGI treated. Immunodetection was performed with a rabbit 
anti-mouse/3-casein or anti-MDGI antibody visualized with a biotin/streptavidin etection system using diaminobenzidine as peroxidase 
substrate. Note marked/5-casein expression in ductal and alveolar MEC, and strong luminal/3-casein secretion if compared to MDGI. 
Bar, 100/~m. 
by high-performance liquid chromatography (BioTez Berlin Buch GmbH). 
Sequences correspond to the mouse MDGI cDNA (6) with the translation 
start as first codon of the sense or the complementary antisense strand. The 
base composition of the random oligonucleotide was made identically to the 
antisense probe. The modified oligonucleotides were directly added to the 
medium on day 1 of the culture. Cultures received th  oligonucleotides with 
every medium change. 
Synthesis of Recombinant Proteins 
Including microheterogeneities found upon protein sequencing in five posi- 
tions (7), MDGI differs from the H-FABP sequence deduced from cDNA 
cloning or protein sequencing (5, 7, 38) in 10 positions of the amino acid 
sequence: 12S in MDGI/D in H-FABP, 14E/K, 40L/T, 36A/T, 43S/E, 
85N/T, 88E/G, 93Q/H, 127V/T, and an additional 132A in H-FABE 
Respective codons were successively exchanged in the H-FABP cDNA 
using the thiophosphate method to obtain the recombinant MDGI form. 
Double-stranded M13mp18DNA was cut by Kpnl and HindIII. The vector 
pET-BHFABE which is a construct of the pET-3d (61) and ofa Ncol/HindIH 
fragment of the H-FABP-cDNA, was used for cloning the MDGI cDNA 
into an expression vector. To this end, an NcoI/HincRII fragment of theun- 
mutated H-FABP cDNA (derived from pET-BHFABP) was replaced by the 
respective MDGI fragment. The resulting expression vector was named 
pET-BHMDGI. To express proteins, the pRT-3d vector in BL21 (DE3) cells 
was used (61). Soluble recombinant proteins were harvested from superna- 
tants and isolated by CM Sephadex C50 and Sephacryl S-100 HR, as de- 
scribed (5). All amino acid substitutions were confirmed by protein se- 
quencing as described (5, 7). Recombinant forms for bovine liver FABP 
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(L-FABP) and rat intestine FABP (I-FABP) were produced according to 
their sequences (68). The mutant human H-FABP carrying 106 Thr for 
Arg was prepared by site-directed mutagenesis u ing the uracil selection 
method (37). 
Fatty Acid Binding 
Fatty acid binding was measured at 2 #M oleic acid and 10/zg protein ac- 
cording to the lipidex method (22) as described by us earlier (9). 
Peptide Synthesis 
Synthesis of peptides with a peptide synthesizer (430A; Applied Bio- 
systems, Inc., Foster City, CA), purification, and identification of purified 
peptides, has been described elsewhere (72). 
Results 
MDGI and Heart FABP Specifically Inhibit Epithelial 
DNA Synthesis 
Protein sequencing showed coexistence in the bovine mam- 
mary gland of H-FABP and of MDGI, which differ from 
each other in 10 amino acids (7). To test whether MDGI and 
H-FABP both possess growth inhibitory activity and 
whether growth inhibition is specific for epithelial cells, the 
respective recombinant and wild-type proteins were pro- 
duced, and were compared in activity in primary cultures of 
MEC (Figs. 1, A and B). As shown, wild-type MDGI at 
10 -9 M specifically inhibited DNA synthesis in MEC (Fig. 
1 A c) if compared to the control (Fig. 1 A a), whereas 
growth of mammary stromal cells was unaffected (Fig. 1 A, 
b and d). Wild-type and recombinant MDGI- or H-FABP in- 
hibited DNA synthesis of MEC by ~50-60% (Fig. 1 B). 
Half-maximal inhibition was obtained with ~10 -1° M of the 
MDGI or H-FABP forms (not shown). Recombinant L- and 
I-FABP, which represent more distant members of the FABP 
family and share an overall sequence homology of 44-55 % 
with MDG! (7), had no significant growth inhibitory effect 
(Fig. 1 B). Therefore, growth inhibition seems to be specific 
for MEC and for MDGI and the heart ype of FABP. 
MDGI Inhibits Ductal Growth and Promotes 
Functional Differentiation 
To ascertain whether MDGI might regulate differentiation, 
whole-organ mammary glands that were derived from vir- 
gin mice were cultured for 5 d in a serum-free medium con- 
taining aldosterone, prolactin, insulin, and hydrocortisone 
(APIH medium) (Fig. 2). This hormone milieu results in 
complete lobuloalveolar development of the gland and ter- 
minates in functional differentiation. Under the same condi- 
tions, organ cultures were treated for 5 d with MDGI at 
10 -9 M. The presence of MDGI resulted in appearance of
smaller ducts and ductules with numerous ide branches 
(Fig. 2 B) when compared with the control (Fig. 2 A). 
H-FABP produced essentially the same morphological 
changes (not shown). Accordingly, when labeling indices 
were estimated in alveoli, ducts and ductules of MDGI- or 
H-FABP-treated mammary glands, strongest inhibition of 
DNA synthesis (*60% if compared to the untreated gland) 
was found in ductular MEC (Table I). In treated cultures, 
ductules were terminated by bulbous alveolar end buds (Fig. 
2 D) when compared with the control gland (Fig. 2 C). The 
Table L Inhibition of Ductal DNA Synthesis by MDGI 
and Bovine H-FABP 
Inhibition of DNA Synthesis (%) 
Protein Alveoli Ducts Ductules Overall 
wt. MDGI 9 +2 34 +4 61 + 6 45 + 5 
wt. H-FABP 13 + 2 33 + 4 57 + 4 46 + 4 
Overall epithelial cell inhibition of DNA synthesis nduced by the recombinant 
forms of MDGI, human H-FABP, and human mutated H-FABP (106Thr for 
106Arg) amounted to 49 5: 5, 40 + 4, 46 -1- 4, and 53 + 5%, respectively. 
Oleic acid binding activities for wild-type and mutant human H-FABP amounted 
to 25.7 and 2.0 nmol/mg protein, respectively. For estimation ofDNA synthe- 
sis, mammary glands were cultured in the APIH medium for 3 d. Epithelial 
cell inhibition of DNA synthesis was determined by labeling cells with BrdU 
for 4 h before cultures were terminated. In controls, ,o16-20% of epithelial 
cells were BrdU positive. Histologic riteria were as follows: ducts, an adja- 
cent layer of connective tissue; ductules, a linear coat of cubic epithelial cells 
without adjacent mesenchyme; alveoli, presence of secretory cells with vacu- 
oles and luminal secretion. 
alveolar end buds represent a developmental pathway that 
eventually leads to secretory alveoli at functional differen- 
tiation. Indeed, histological examination of MDGI-treated 
glands revealed the appearance of mono-layered secretory 
active alveoli with enlarged luminal spaces (Fig. 2, E and F). 
In accord with these changes, which are characteristic for 
the differentiated phenotype, functional differentiation evi- 
denced by B-casein expression was stimulated (Fig. 2, G and 
H). Intracellular and luminal B-casein levels, which can be 
considered to indicate an earlier period of functional 
differentiation, were elevated (Fig. 2 H). MDGI treatment 
produced an autostimulation f its mRNA expression (Table 
II). Correspondingly, a clear increase in endogenous MDGI 
production was detected inMEC and, to a much less extent, 
in the luminal spaces (Figs. 2, I and J). The striking differ- 
ences between the pattern of the B-casein and MDGI expres- 
sion exactly reflect he situation we have described for the 
developing mammary gland (6). Substantiation that MDGI, 
as well as the human and bovine forms of H-FABP, might 
function as differentiation factors in the mammary gland was 
assessed by quantifying "early" and "late" markers of func- 
tional differentiation such as B-casein and WAP expression, 
fat droplet accumulation, and secretory activity (Table ID. 
As shown, MDGI and H-FABP elevated the levels of markers 
for functional differentiation up to threefold. 
Inhibition of MDGI Expression Suppresses Alveolar 
Differentiation and f3-Casein Expression 
In mammary glands of primed virgin mice, the MDGI gene 
is not expressed; however, if these glands are taken in culture 
in presence of APIH, MDGI expression can be first detected 
after 3 d (6). Hormonally induced MDGI expression, which 
reaches some maximum after 8 d (6), follows closely the pat- 
tern that has been found during pregnancy (6, 38). This 
finding argues in favour of a local role for endogenous MDGI 
during growth and differentiation, and we have therefore 
tested whether MDGI expression is a prerequisite for normal 
development. Tothis end, antisense phosphothioate oligonu- 
cleotides complementary to position 1-17 (relative to the 
translation i itiation side) of the murine MDGI coding re- 
gion (6) (as-oligonucleotide) were added on day 1 to the 
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Table 11. Stimulation of Functional Differentiation by MDGI and H-FABP 
mRNA Levels 
Protein B-casein WAP MDGI Fat droplet index Alveolar secretion 
(%) (%) (%) 
wt. MDGI 295 + 12 275 + 10 295 + 10 179 + 21 153 + 18 
wt. bovine H-FABP 280 + 10 287 + 15 267 4- 12 195 + 19 157 + 17 
Rec. human H-FABP 241 + 4 251 + 9 255 + 10 218 + 13 271 + 22 
Rec. human mut. H-FABP 251 + 6 260 + 7 282 4- 9 210 + 10 248 + 13 
Mammary glands were cultured for 5 d in the APIH medium. Levels are expressed as percent of the RNA level in the control representing the contralateral gland. 
Three pairs of contralaterai glands were examined. For definition of morphometric parameters, ee Materials and Methods. 
APIH-maintained whole organ cultures. Controls included 
the sense (s) and one random (r) oligonucleotide. As shown 
in Fig. 3 B, a 5-d treatment with the as-oligonucleotide al- 
most completely blocked MDGI expression i MEC if com- 
pared with the untreated control gland (Fig. 3 A). Whole- 
mount stains of two pairs of contralateral glands (Fig. 3, C 
and D) demonstrate he typical morphological effect ob- 
served upon as-oligonucleotide tr atment. Glands placed on 
the right side of Fig. 3, C and D, received as-oligonucleotide, 
whereas left glands represent the respective control glands. 
As can be seen, inhibition of MDGI expression leads to 
prevention of alveolar end bud formation and to the appear- 
ance of glands that seem to be retarded in development. The 
two other control glands, which received the s-oligonucleo- 
tide (Fig. 3 E, right gland) or r-oligonucleotide (Fig. 3 F, 
right side) show the same normal development asthe corre- 
sponding untreated glands, depicted on the left side in Figs. 
3, E and E As could be expected, the appearance ofless de- 
veloped glands was accompanied by a fourfold increase in 
the labeling index of ductai and ductular epithelial cells (not 
shown). In accord with impaired alveolar growth shown in 
Fig. 3, C and D, we found profoundly decreased/~-casein lev- 
els in as-oligonucleotide-treated glands (Fig. 3 H), if com- 
pared to the normal control (Fig. 3 G). This was particularly 
evident for the luminal species of alveoli, compared to the 
intracellular/3-casein level, which was somewhat less af- 
fected. 
MDGI and EGF Are Functional Antagonists 
We showed recently that EGF strongly suppresses MDGI 
mRNA expression and prevents differentiation i explant 
cultures derived from virgin or pregnant mouse mammary 
glands (6, 59). It was, therefore, obvious to ascertain 
whether EGF and MDGI might functionally interact during 
growth and differentiation. To this end, organ cultures were 
treated for 5 d with both factors in a concentration range of 
1-3 nM (Fig. 4). As shown, EGF exerts mitogenic activities 
and suppresses the mRNA levels for WAP, ~casein, and 
MDGI. The effects of EGF on growth and differentiation 
were suppressed with increasing MDGI concentrations. 
MDGI at 3 nM completely prevented activities of 1 nM EGF. 
On the other side, stimulation of functional differentiation by
MDGI could be strongly reduced in presence of 3 nM EGF. 
In conclusion, increasing the EGF or the MDGI concentra- 
tions was mutually antagonistic. 
The Activities of MDGI Do Not Depend on Fatty 
Acid Binding and Can Be Mimicked by an ll-Amino 
Acid Sequence Represented in the COOH terminus 
of MDGI and Related FABPs 
The physiological role of retinoids, eicosanoids, or long- 
chain fatty acids endogenously bound to FABPs is unclear. 
We, therefore, tested whether bound fatty acids could be 
directly involved in the biological activities. The first ap- 
proach was to produce arecombinant FABP form that cannot 
bind fatty acid. Replacement of 106 Arg by Thr in human 
H-FABP abolished the capacity of H-FABP to bind oleic 
acid, however, did not affect its growth inhibitory (Table I) 
or differentiation stimulating (Table ID activities. This 
finding supports a mechanism not involving bound fatty 
acids. Direct evidence was obtained for a functional domain 
in MDGI that does not require lipid binding by testing vari- 
ous synthetic peptides of the COOH-terminal MDGI se- 
quence. By comparing FABP sequences ncoded by exon 4, 
a striking homology was detected for a COOH-terminal 
stretch of 11 amino acids (designated as P108) (Fig. 5 A). 
Notably, we have shown earlier that P108 does not bind fatty 
acids (72). P108 at 10 -1° M inhibited DNA synthesis of pri- 
mary MEC by 55 % (not shown), and was therefore further 
tested in the organ culture system under conditions as de- 
scribed before for MDGI (Fig. 5 B, a-d). Analogous to 
MDGI, treatment of APIH-cultured mammary glands for 
5 d with 10 -9 M P108 affected uctal branching and caused 
appearance of more bulbous alveolar end buds (Fig. 5 B, a 
and b). In accordance with the morphological changes that 
suggest suppression ofductal growth by P108, we found that 
after 3 d, DNA synthesis in MEC was inhibited by •60% 
(Fig. 5 C). Prolonged treatment for 5 d of the mammary 
glands with 10 -9 M P108 resulted in the appearance of 
differentiated pithelium characterized bymonolayered, se- 
cretory active alveoli (Fig. 5 B, c and d). In parallel, and 
similarly to MDGI t-casein synthesis was clearly stimulated 
by P108 (not shown). The growth inhibitory and differentia- 
tion stimulating activities of P108 are summarized in Fig. 5 
C. As shown, the 11 COOH-terminal residues of MDGI are 
sufficient to fully mimic the activities of MDGI, including 
stimulation of B-casein and WAP expression, as well as au- 
tostimulation ofendogenous MDGI gene expression. Single 
replacements of 130Lys by Asn or of 128Tyr by Ala abol- 
ished the activities of P108. Two other peptides including a 
shorter sequence of P108 (residues 126-130), representing a 
functional domain of growth hormone (42), were inactive. 
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Figure 3. Effect of inhibition of MDG! expression on differentiation. Whole organ cultures of mammary glands maintained for 5 d in the 
APIH medium received 10 ~M of a modified antisense oligonucleotide complementary to position 1-17 of the MDGI encoding region. 
Immunostains for MDGI show inhibition of MDGI expression (B) ff compared with the torero! contralateral gland (,4). Bar, 50 pro. Whole 
mount stains of mammary glands treated with the antisense (as) oligonucleotide (glands hown on the right side of C and D) show the 
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Figure 3. 
Discuss ion  
We demonstrate here for the first time that a polypeptide 
growth inhibitor promotes morphological and functional 
differentiation i  the developing nmnunary gland. The in 
vitro model we have been using ensures to follow ductal 
growth and branching, lobuloalveolar development, and 
functional differentiation, i.e., developmental stages nor- 
mally occurring during pregnancy. We were, therefore, able 
to test for both growth and ifferentiation activities of 
MDGI. It turned out that MDGI, which is expressed in the 
mammary gland in a developmentally and hormonally regu- 
lated manner (6, 38, 43), specifically inhibits epithelial DNA 
synthesis, promotes formation of alveolar buds, supports de- 
velopment of differentiated lobuloalveoli, and stimulates 
milk protein synthesis and fat droplet accumulation. This 
means that MDGI stimulates both "early" and "late" phases 
(more characterized by fat droplet accumulation) of func- 
tional differentiation. 
These are all the properties that distinguish MDGI from 
TGF-/31, which strongly inhibits ductal outgrowth in virgin 
mice; however, it does not affect epithelial growth during 
later stages of development like pregnancy. Moreover, con- 
trary to MDGI, TGF-/31 does impair functional differentia- 
tion in vitro (41, 50) and in vivo (34). Therefore, MDGI can 
Figure 4. Functional interaction between MDGI
and EGF. Mammary glands were cultured for 5 d 
in the presence of APIH. MDGI and EGF were ad- 
ditionally present at the indicated concentrations 
for 5 d. Overall epithelial DNA synthesis ex- 
pressed as labeling index (/.2) was determined by
labeling cells with BrdU for4 h before cultures 
were terminated, and mRNAs levels were esti- 
mated from Northern blots hybridized with 32p_ 
labeled probes as outlined before. Values ar  ex- 
pressed as percent of the control representing the 
contralateral gland. Three pairs of contralateral 
glands were examined. 
effect on lobuloalveolar development in comparison to the untreated control gland, placed on th  left side. Shown aretwo typical pairs 
of mammary glands. Note almost complete regression of alveolar end buds in glands treated with the as-oligonucleotide. E and F represent 
control glands treated for 5 d with the sense probe (E, gland on right) or with the random oligonucleotide (F,right side), while the respective 
untreated contralateral glands are shown on the left side. (G and H) Sections immunostained for B-casein expression derived either from 
the gland treated with the as-oligonucleotide (H) or from the untreated contralateral gland (G). Note preferential reduction of luminal 
immunostaining. Bar, 100 #m. 
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Figure 5. Effects of P108 on growth and differentiation of the mammary gland in organ culture. (A) Comparison of the COOH-terminal 
sequence of bovine MDGI (7) with sequences of bovine brain FABP (52), bovine heart FABP (5), bovine myelin P2 (68), mouse P422 
(68), and bovine CRABP (68). Areas containing identical or conservatively exchanged residues are shadowed. Residues 126-131 are identi- 
cal to residues 108-112 of bovine growth hormone (42), and they are bordered by two highly conserved positively charged amino acids. 
Biologically active P108 comprises residues 12M 31 in which cysteine has been replaced by serine to prevent dimerization a d inactivation 
(72). Numbering is according to the MDGI sequence in (7). For comparison, sequences of inactive bovine L-FABP and rat I-FABP are 
included. (B) Effects of P108 on morphology and histology. Glands were cultured for 5 d in APIH medium in the absence (a and c) or 
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be considered as a unique and novel differentiation factor for 
the mammary gland. 
Functionally, MDGI and the bovine and human forms of 
H-FABP can not be distinguished. Considering that at least 
one other member of the family, the brain FABP, has been 
described to be identical with MDGI (52), one can assume 
a role for these proteins in tissue differentiation. This as- 
sumption concurs with data from an earlier study (73), 
where we have shown that teratocarcinomas formed in syn- 
genie mice after injection of pluripotent embryonic stem 
cells treated with MDGI or P108 contain more differentiated 
neural tissue. 
Interestingly, an immunohistochemical analysis of MDGI 
and H-FABP expression shows immunoreactivity exclu- 
sively in postmitotic, terminally differentiated cells of the 
myocard, skeletal muscle, and surface pithelial cells of in- 
testinal and respiratory tracts (Zschiesche, W., A. Kleine, 
J. H. Veerkamp, and J. Glatz, manuscript submitted for pub- 
lication). The developmental, cell and tissue specific expres- 
sion of various other FABPs (14, 15, 28, 30) indeed seems 
to support a more general role for these proteins in growth 
and differentiation similarly to that described here for 
MDGI. 
MDGI expression can be hormonally induced in organ 
culture and its synthesis is further stimulated when MDGI 
or P108 were added. To test for a relationship between en- 
dogenous MDGI expression and a function of MDGI during 
development, we have inhibited MDGI expression i MEC. 
Our findings about a suppression of alveolar growth and 
/S-casein synthesis might indicate an intracellular mode of 
action and again indicate to MDGI as a differentiation factor. 
This is in correspondence with the specific pattern of gene 
expression during pregnancy showing MDGI transcripts 
preferentially in alveolar cells adjacent to the surrounding 
stroma (38). In contrast to the situation i organ cultures, 
MDGI can not be induced in MEC grown as monolayers, in- 
eluding responsive to lactogenic hormones murine cell lines 
(unpublished ata). Single MEC provided with an exoge- 
nous basement membrane that can be induced to express 
/3-casein also do not express MDGI unless they form mul- 
ticellular structures with luminal spaces (unpublished data). 
These data and our present findings strongly argue in favor 
of a role for MDGI at a distinct state of development that is 
characterized bya decline of ductal growth and is associated 
with lobuloalveolar morphogenesis and functional differenti- 
ation. 
It has been recently reported about a structural identity be- 
tween MDGI and a cysteine protease inhibitor specific for 
papain, cathepsin B and cathepsin L (74). It is tempting to 
speculate that the high level of MDGI expression found in 
the lactating mammary gland and in milk (12), suggests a
different function which might rather be associated with lipid 
transport and metabolism, tissue remodeling, or with pre- 
serving milk protein products. Our findings about a domi- 
nant presence of MDGI in cells with high steroid metabolism 
such as testicular Leydig' cells, adrenal cells, or cells of the 
corpus luteum, might indicate future directions of work 
(Zschiesche, W., A. Kleine, J. H. Veerkamp, and J. Glatz, 
manuscript submitted for publication): 
In breast cancer cells, the antiproliferative activity of 
MDGI can be antagonized by EGF in a dose-dependent 
manner (10, 23). EGF and TGF-c~ strongly suppress MDGI 
mRNA expression i explant and organ cultures of pregnant 
or virgin mice (6, 59). On the other hand, several lines of 
indirect evidence indicate that EGF might have a role in 
differentiation. The levels of EGF in plasma (46.) and its 
receptor in the mammary gland (20) increase during preg- 
nancy. Both EGF and TGF-ot have been detected in the mam- 
mary epithelium of pregnant mice (55, 59). However, 
conflicting reports about EGF or TGF-t~ activities demon- 
strated both differentiation-inhibiting (31,64, 71) and-stim- 
ulating activities (71). According to our data, EGF is able 
to produce agrowth stimulatory effect on MEC under condi- 
tions of functional differentiation, provided that MDGI was 
absent or added at low concentrations. The data show that 
increasing the EGF or MDGI concentration was mutually 
antagonsitic. We have shown earlier that EGF suppresses 
MDGI mRNA expression (6), suggesting that under physio- 
logical conditions, concentration of both factors might be 
critical for maintaining balanced growth and differentiation. 
In early pregnancy, when EGF and TGF-a are present, they 
could suppress MDGI overexpression, thus preventing im- 
paired growth and differentiation of the mammary gland. 
Likewise, MDGI could regulate EGF activities to maintain 
normal differentiation. 
Our findings about growth inhibitory and differentiation 
promoting activities of human and bovine H-FABP provide 
first direct evidence fora regulatory function of members of 
this conservative multigene family. Based on expression 
data, it has been suggested that some FABPs might have 
in the presence (b and d) of 10 -9 M of the synthetic peptide P108. Whole mount stain of P108 treated gland shows bulbous alveolar end 
buds (b). Histology shows monolayered secretory active epithelium upon peptide treatment (d). Bar, 50/~ . (C) Peptide P108 fully mimics 
growth and differentiation properties of MDGI. Whole mammary glands were cultured for 3 d to determine the labeling index in MEC, 
or for 5 d (to estimate the mRNA levels for MDGI, WAP and/S-casein) in the APIH medium in presence of 1 nM of the different peptides. 
To verify specificity of P108, LIs were determined with modified peptides: 130Lys-'*130Asn, designated as P206; 128Tyr-*128Ala, desig- 
nated as P207. In addition, amino acids 69-78 and 126-130 of the MDGI sequence are represented by P14 and P104, respectively. 
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some function in cellular growth, differentiation, and signal 
transduction (21, 69). For the I-FABP, endogenous expres- 
sion in cryptal cells of the intestinum is strictly associated 
with inhibition of DNA synthesis (15). However, a dominant 
expression in more differentiated cells described for the 
I-FABP (15), the adipocyte FABP, (also referred to as ap2 or 
P422 [57]), or for the CRABP (14) has not been directly 
related to growth inhibitory activity. Unexpectedly, transfec- 
tion of liver eDNA into hepatoma cells (36) or fibroblasts 
(33) cause these cells to grow in response to linoleic acid and 
to reach higher cell densities, respectively. Overexpressing 
CRABP-1 in F9 teratocarcinoma cells resulted in reduction 
of differentiation (11). However, there are no data available 
to show the consequences of overexpression of FABPs into 
normal cells, which can be induced to undergo differentia- 
tion in vitro. We report here that I'108, which represents the 
COOH terminus of MDGI, fully mimics the MDGI proper- 
ties. This peptide has a strong homology with the COOH ter- 
minus of other FABPs, including myelin P2, which is ex- 
pressed during differentiation of Schwann's cells (28), with 
CRABP and brain FABP. PI08 does not bind fatty acids (72) 
rendering involvement of endogenously bound ligands in the 
activities we described here very unlikely. Rather, our data 
argue in favor of a mechanism implying interaction of P108 
with cellular targets related to growth signaling pathways. 
For the CRABP, a function in signaling pathways has been 
suggested (19). 
Although the molecular mechanism(s) by which MDGI or 
P108 inhibit growth and promote differentiation are not yet 
known, preliminary data indicate steps likely to be involved. 
We have shown that PI08 over a concentration range of 
10 -~° to 10 -m: M prevents arachidonic acid or 15S-hydroxy- 
eicosatetraenoic acid-induced hypersensitivity of neonatal 
rat heart cells to /3~-adrenergic stimulation (72). From 
these studies, we concluded that a mechanism of interference 
of MDGI or P108 subsequent to generation of 15S-hydroxy- 
eicosatetraenoic a id is involved. Among the different pep- 
tides tested, only P108 turned out to be active in MEC and 
heart myocytes. Therefore, it seems possible that the growth 
modulatory effects of MDGI and of P108 may result from an 
interference with some pathway subsequent to the generation 
of lipoxygenase products. For TNF (25), IFN-o~ (26), and 
TGF-/~ (45), involvement of the arachidonic acid pathway has 
been documented. 
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